Risk Factors of CJC-1295 CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analogue, has been investigated as a stimulant of GH and IGF-I secretion in healthy adults, who tolerated it well at doses of 30 or 60 microg/kg, although at 100 micro g/kg adverse reactions (mainly gastrointestinal) proved more frequent
Eligibility is selective, with strict BMI, age, comorbidity, and previous-treatment criteria, and some participants receive placebo (a dummy version of the drug)
In clinical trials , Zepbound produced weight loss results of 15%21% in 72 weeks (about a year and five months)
It canespecially if youre already dealing with some side effects from taking Zepbound
doi: 10.1126/science.1063127 66 JewellJ